Bajaj Healthcare (BHL) announced that it has entered into a definitive CDMO agreement with esteemed UK/EU based customers for the supply of 15 Active Pharmaceutical Ingredient (APIs). Under this agreement, BHL will undertake the development and supply of these molecules, which will be exclusively manufactured for its clientele. These APIs encompass a diverse range of compounds, including off-patent generics and molecules soon to be off-patent. The CDMO agreement will be executed through its in-house R&D and manufacturing capacities at Savli Vadodara, Gujarat.Powered by Capital Market - Live News

Net loss of Bajaj Healthcare reported to Rs 2.20 crore in the quarter ended December 2023 as against net profit of Rs 11.05 crore during the previous quarter ended December 2022. Sales declined 18.10% to Rs 108.57 crore in the quarter ended December 2023 as against Rs 132.57 crore during the previous quarter ended December 2022. ParticularsQuarter Ended�Dec. 2023Dec. 2022% Var. Sales108.57132.57 -18 OPM %17.9822.96 - PBDT13.6725.14 -46 PBT6.3220.71 -69 NP-2.2011.05 PL Powered by Capital Market - Live News

Bajaj Healthcare will hold a meeting of the Board of Directors of the Company on 9 February 2024.Powered by Capital Market - Live News

Net loss of Bajaj Healthcare reported to Rs 3.46 crore in the quarter ended September 2023 as against net profit of Rs 16.36 crore during the previous quarter ended September 2022. Sales declined 48.18% to Rs 101.21 crore in the quarter ended September 2023 as against Rs 195.32 crore during the previous quarter ended September 2022. ParticularsQuarter Ended�Sep. 2023Sep. 2022% Var. Sales101.21195.32 -48 OPM %18.7117.63 - PBDT11.9030.92 -62 PBT5.2426.92 -81 NP-3.4616.36 PL Powered by Capital Market - Live News

Bajaj Healthcare will hold a meeting of the Board of Directors of the Company on 9 November 2023.Powered by Capital Market - Live News